Questions About COVID-19?

Find information here

These are extraordinary times—we’re here to help

At Novartis, we are committed to the health and well-being of our patients, and we are closely monitoring the coronavirus (COVID-19) situation. Here, you will find helpful links that may answer some of your questions.


It's important that you take precautions to reduce the risk of contracting COVID-19 and contact your prescribing health care provider if you have any questions or concerns about your treatment with ADAKVEO® (crizanlizumab-tmca).


You can also reach out to 1-888-NOW-NOVA (1-888-669-6682) Monday–Friday, 8:30 AM – 5:00 PM ET with any questions.


To learn more about how Novartis is responding to COVID-19, visit

We're in this together. It's important to take COVID-19 and your health seriously.


The Centers for Disease Control and Prevention (CDC) have put together a helpful list of actions to take if you have sickle cell disease (SCD). This list contains resources that may be helpful for you and your loved ones.


Information is power. The Secure-SCD Registry aims to capture adult COVID-19 cases occurring across the world in patients living with sickle cell disease. The goal of the registry is to report on outcomes of COVID-19 cases in the SCD patient population. Reporting an infection of COVID-19 takes only minutes. Learn more here.


Where can I find additional resources?


To follow the latest information on COVID-19, visit the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO).

Novartis response to COVID-19



Novartis COVID-19 Response Fund is providing urgently needed support for health care workers and communities in more than 50 projects around the world.


Novartis established a $20 million Global Response Fund in mid-March to support communities around the world impacted by the COVID-19 pandemic. The fund aims to support public health initiatives designed to help communities manage the challenges posed by the pandemic, such as programs to strengthen health care infrastructure, digital platforms for data collection or dissemination of important public health information, and community health programs.


To learn more about how Novartis is responding to COVID-19, visit